Back to Search
Start Over
Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
- Source :
-
Inflammatory bowel diseases [Inflamm Bowel Dis] 2018 Feb 15; Vol. 24 (3), pp. 465-466. - Publication Year :
- 2018
Details
- Language :
- English
- ISSN :
- 1536-4844
- Volume :
- 24
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Inflammatory bowel diseases
- Publication Type :
- Editorial & Opinion
- Accession number :
- 29462402
- Full Text :
- https://doi.org/10.1093/ibd/izx092